Calliditas Therapeutics AB (publ)
CALT · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $6,956 | $4,690 | $5,687 | $6,199 |
| - Cash | $974 | $1,249 | $956 | $996 |
| + Debt | $979 | $729 | $213 | $5 |
| Enterprise Value | $6,962 | $4,170 | $4,945 | $5,208 |
| Revenue | $1,207 | $803 | $229 | $1 |
| % Growth | 50.3% | 250.1% | 26,141.1% | – |
| Gross Profit | $1,130 | $788 | $229 | $1 |
| % Margin | 93.6% | 98.1% | 100% | 100% |
| EBITDA | -$368 | -$389 | -$472 | -$379 |
| % Margin | -30.5% | -48.4% | -205.7% | -43,409.4% |
| Net Income | -$466 | -$412 | -$510 | -$437 |
| % Margin | -38.6% | -51.3% | -222.2% | -49,944.1% |
| EPS Diluted | -17.38 | -15.56 | -20.04 | -19.46 |
| % Growth | -11.7% | 22.4% | -3% | – |
| Operating Cash Flow | -$435 | -$311 | -$462 | -$309 |
| Capital Expenditures | -$13 | -$3 | -$23 | $0 |
| Free Cash Flow | -$447 | -$314 | -$484 | -$309 |